Regeneron Pharmaceuticals (REGN)

$567.74 +7.98 (1.43%)
Market Cap 61.30B
Revenue (ttm) 14.20B
Net Income (ttm) 4.41B
EPS (ttm) N/A
PE Ratio 14.67
Forward PE 19.62
Profit Margin 31.07%
Debt to Equity Ratio 0.07
Volume 844,600
Avg Vol 1,346,566
Day's Range N/A - N/A
Shares Out 107.97M
Stochastic %K 99%
Beta 0.33
Analysts Strong Sell
Price Target $736.75

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to...

Industry: Biotechnology
Sector: Healthcare
Phone: 914 847 7000
Address:
777 Old Saw Mill River Road, Tarrytown, United States
Lach14
Lach14 Jul. 13 at 2:41 AM
REGENERON After a 60% drop from June 28, 2024, $REGN is breaking out above 50 DMA (orange line). Some biotech stocks a bit oversold. $AMGN $SPY $QQQ
0 · Reply
ProKnifeCatcher87
ProKnifeCatcher87 Jul. 11 at 11:31 PM
$REGN $1,750 fv.., pipeline $IBB
0 · Reply
stockswinger14
stockswinger14 Jul. 11 at 9:46 PM
$REGN $700+ obviously isn’t a guarantee, but I think it’s pretty close 😎
1 · Reply
NolAsrtormZ
NolAsrtormZ Jul. 11 at 7:06 PM
$VERU ... $SRRK $NVO $REGN 🤑🤪🤑🤪
0 · Reply
JarvisFlow
JarvisFlow Jul. 11 at 7:00 PM
UBS updates rating for Regeneron Pharmaceuticals ( $REGN ) to Neutral, target set at 560 → 584.
1 · Reply
Smci2xtoday
Smci2xtoday Jul. 11 at 6:46 PM
$REGN jpm price raised price target to 800
0 · Reply
stockswinger14
stockswinger14 Jul. 11 at 5:49 PM
$REGN lets go into the weekend above $566
0 · Reply
IN0V8
IN0V8 Jul. 11 at 5:34 PM
$REGN UBS raises target price to $584 from $560
1 · Reply
Quantumup
Quantumup Jul. 11 at 12:36 PM
Raymond James🏁 $JANX Outperform-$65 and said, "We are initiating coverage of Janux Therapeutics (JANX) with an Outperform rating and $65 price target." $AMGN $REGN $JNJ Raymond James added, "Janux is clinical-stage company focused on developing masked T-cell engagers (TCEs) for the treatment of several cancer types. Our investment thesis is predicated on four key points: Preliminary 3L+ PSA results for JANX007 (PSMA x CD3) in mCRPC are compelling at higher doses. We see results to date, while not entirely devoid of TCE-related toxicities, as strong proof-of-concept for the masking technology employed by Janux. We see a sizable opportunity for JANX007 in prostate cancer, a large market with room for several players targeting PSMA in earlier lines and in sequence. We do not currently credit Janux for revenues from other pipeline assets, and thus we see JANX008 (EGFR x CD3), and the rest of the platform/early assets, as entirely upside potential. Raymond James went on to say:
1 · Reply
JTebow_CWS
JTebow_CWS Jul. 11 at 9:03 AM
$SABS $REGN Excellent explanation of polyclonal antibodies. Definitely the Lord’s amazing design.
3 · Reply
Latest News on REGN
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025

Jul 10, 2025, 9:15 AM EDT - 2 days ago

Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

Jul 2, 2025, 11:45 AM EDT - 10 days ago

Regeneron Gets Accelerated FDA OK of Lynozyfic for Blood Cancer Treatment

US FDA approves Regeneron's blood cancer therapy

Jul 2, 2025, 11:11 AM EDT - 10 days ago

US FDA approves Regeneron's blood cancer therapy

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

Jun 26, 2025, 4:05 PM EDT - 16 days ago

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade

Jun 25, 2025, 9:19 AM EDT - 17 days ago

Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

Jun 24, 2025, 7:30 AM EDT - 18 days ago

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

Jun 23, 2025, 6:10 PM EDT - 19 days ago

Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz

AMGN GPCR LLY NVO PFE VKTX XBI

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease

Jun 20, 2025, 2:01 AM EDT - 23 days ago

Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease

SNY

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Jun 20, 2025, 1:00 AM EDT - 23 days ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

SNY

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Jun 20, 2025, 1:00 AM EDT - 23 days ago

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer

Jun 16, 2025, 5:23 PM EDT - 26 days ago

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer

Former 23andMe CEO Anne Wojcicki wins bid for control of her former company, topping Regeneron

Jun 16, 2025, 7:06 AM EDT - 26 days ago

Former 23andMe CEO Anne Wojcicki wins bid for control of her former company, topping Regeneron

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Jun 15, 2025, 11:22 AM EDT - 27 days ago

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

SNY

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

Jun 15, 2025, 11:21 AM EDT - 27 days ago

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research

Jun 11, 2025, 9:00 AM EDT - 4 weeks ago

Regeneron CEO on 23andMe bid: Trying to balance individual privacy with biotech & genetics research

Regeneron Pharma Shares Rise Over 3% After Key Signal

Jun 10, 2025, 7:48 AM EDT - 4 weeks ago

Regeneron Pharma Shares Rise Over 3% After Key Signal

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript

Jun 9, 2025, 12:44 PM EDT - 4 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Jun 7, 2025, 6:30 PM EDT - 5 weeks ago

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Why Regeneron Is Falling And Why You Should Avoid It

Jun 4, 2025, 11:19 AM EDT - 5 weeks ago

Why Regeneron Is Falling And Why You Should Avoid It

REGN Stock Undervalued At $500?

Jun 2, 2025, 9:10 AM EDT - 5 weeks ago

REGN Stock Undervalued At $500?

Regeneron's weight-loss drug helps preserve muscle mass in study

Jun 2, 2025, 7:12 AM EDT - 5 weeks ago

Regeneron's weight-loss drug helps preserve muscle mass in study

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

Jun 2, 2025, 7:05 AM EDT - 5 weeks ago

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

May 31, 2025, 8:04 AM EDT - 6 weeks ago

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet

May 30, 2025, 5:35 PM EDT - 6 weeks ago

S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet

ULTA

Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure

May 30, 2025, 3:19 PM EDT - 6 weeks ago

Regeneron dashes Wall Street's hopes as COPD treatment trial suffers a failure

Itepekimab Failure A Setback For Sanofi And Regeneron

May 30, 2025, 2:10 PM EDT - 6 weeks ago

Itepekimab Failure A Setback For Sanofi And Regeneron

SNY

Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More

May 30, 2025, 12:30 PM EDT - 6 weeks ago

Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More

COO ULTA

Regeneron stock crashes on COPD data: here's why I'm buying REGN today

May 30, 2025, 12:04 PM EDT - 6 weeks ago

Regeneron stock crashes on COPD data: here's why I'm buying REGN today

Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session

May 30, 2025, 9:10 AM EDT - 6 weeks ago

Elastic, Gap, Regeneron Pharmaceuticals And Other Big Stocks Moving Lower In Friday's Pre-Market Session

ESTC GAP

Regeneron shares slide on mixed trial data on smoker's lung drug

May 30, 2025, 6:37 AM EDT - 6 weeks ago

Regeneron shares slide on mixed trial data on smoker's lung drug

Sanofi, Regeneron's Itepekimab Delivers Mixed Results in Late-Stage Trials

May 30, 2025, 3:19 AM EDT - 6 weeks ago

Sanofi, Regeneron's Itepekimab Delivers Mixed Results in Late-Stage Trials

SNY

Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair

May 28, 2025, 4:29 PM EDT - 6 weeks ago

Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

May 28, 2025, 9:00 AM EDT - 6 weeks ago

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

May 22, 2025, 5:00 PM EDT - 7 weeks ago

Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

What Regeneron's Purchase Of 23andMe Means For Your Genetic Privacy

May 21, 2025, 4:35 PM EDT - 7 weeks ago

What Regeneron's Purchase Of 23andMe Means For Your Genetic Privacy

Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains

May 21, 2025, 6:15 AM EDT - 7 weeks ago

Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains

Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)

May 20, 2025, 3:24 PM EDT - 7 weeks ago

Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)

Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD)

May 20, 2025, 7:30 AM EDT - 7 weeks ago

Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD)

SNY

Regeneron acquires bankrupt 23andMe, pledges ethical use of genetic data

May 19, 2025, 3:15 PM EDT - 7 weeks ago

Regeneron acquires bankrupt 23andMe, pledges ethical use of genetic data

Regeneron Buys 23andMe in Bankruptcy Auction

May 19, 2025, 1:05 PM EDT - 7 weeks ago

Regeneron Buys 23andMe in Bankruptcy Auction

Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions

May 19, 2025, 12:39 PM EDT - 7 weeks ago

Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions

Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal

May 19, 2025, 11:51 AM EDT - 7 weeks ago

Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal

Pharma giant Regeneron to buy 23andMe and its customers' data for $256M

May 19, 2025, 10:35 AM EDT - 7 weeks ago

Pharma giant Regeneron to buy 23andMe and its customers' data for $256M

Cramer's Stop Trading: Regeneron

May 19, 2025, 10:34 AM EDT - 7 weeks ago

Cramer's Stop Trading: Regeneron

Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million

May 19, 2025, 10:14 AM EDT - 7 weeks ago

Regeneron Pharmaceuticals to buy 23andMe and its data for $256 million

23andMe sells its most valuable asset. Regeneron promises keep your DNA private.

May 19, 2025, 8:40 AM EDT - 7 weeks ago

23andMe sells its most valuable asset. Regeneron promises keep your DNA private.

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million

May 19, 2025, 7:48 AM EDT - 7 weeks ago

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million

Regeneron to buy bankrupt genetic testing firm 23andMe for $256 million

May 19, 2025, 7:43 AM EDT - 7 weeks ago

Regeneron to buy bankrupt genetic testing firm 23andMe for $256 million

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

May 19, 2025, 7:07 AM EDT - 7 weeks ago

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale

May 19, 2025, 7:04 AM EDT - 7 weeks ago

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale

Lach14
Lach14 Jul. 13 at 2:41 AM
REGENERON After a 60% drop from June 28, 2024, $REGN is breaking out above 50 DMA (orange line). Some biotech stocks a bit oversold. $AMGN $SPY $QQQ
0 · Reply
ProKnifeCatcher87
ProKnifeCatcher87 Jul. 11 at 11:31 PM
$REGN $1,750 fv.., pipeline $IBB
0 · Reply
stockswinger14
stockswinger14 Jul. 11 at 9:46 PM
$REGN $700+ obviously isn’t a guarantee, but I think it’s pretty close 😎
1 · Reply
NolAsrtormZ
NolAsrtormZ Jul. 11 at 7:06 PM
$VERU ... $SRRK $NVO $REGN 🤑🤪🤑🤪
0 · Reply
JarvisFlow
JarvisFlow Jul. 11 at 7:00 PM
UBS updates rating for Regeneron Pharmaceuticals ( $REGN ) to Neutral, target set at 560 → 584.
1 · Reply
Smci2xtoday
Smci2xtoday Jul. 11 at 6:46 PM
$REGN jpm price raised price target to 800
0 · Reply
stockswinger14
stockswinger14 Jul. 11 at 5:49 PM
$REGN lets go into the weekend above $566
0 · Reply
IN0V8
IN0V8 Jul. 11 at 5:34 PM
$REGN UBS raises target price to $584 from $560
1 · Reply
Quantumup
Quantumup Jul. 11 at 12:36 PM
Raymond James🏁 $JANX Outperform-$65 and said, "We are initiating coverage of Janux Therapeutics (JANX) with an Outperform rating and $65 price target." $AMGN $REGN $JNJ Raymond James added, "Janux is clinical-stage company focused on developing masked T-cell engagers (TCEs) for the treatment of several cancer types. Our investment thesis is predicated on four key points: Preliminary 3L+ PSA results for JANX007 (PSMA x CD3) in mCRPC are compelling at higher doses. We see results to date, while not entirely devoid of TCE-related toxicities, as strong proof-of-concept for the masking technology employed by Janux. We see a sizable opportunity for JANX007 in prostate cancer, a large market with room for several players targeting PSMA in earlier lines and in sequence. We do not currently credit Janux for revenues from other pipeline assets, and thus we see JANX008 (EGFR x CD3), and the rest of the platform/early assets, as entirely upside potential. Raymond James went on to say:
1 · Reply
JTebow_CWS
JTebow_CWS Jul. 11 at 9:03 AM
$SABS $REGN Excellent explanation of polyclonal antibodies. Definitely the Lord’s amazing design.
3 · Reply
gargoyl
gargoyl Jul. 11 at 2:54 AM
$BLRX 👀 1 of 4 BiolineRx is about to explode $REGN watch peeps 🐥
0 · Reply
BenTheDo
BenTheDo Jul. 11 at 12:36 AM
$REGN guess we aren't hearing the PDUFA news that isnt a good sign....
2 · Reply
Kohain
Kohain Jul. 10 at 10:40 PM
$REGN when will we hear about pdufa for today?
1 · Reply
kenbkb
kenbkb Jul. 10 at 8:02 PM
$REGN Great SEEKING ALPHA read w great comments as well Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
0 · Reply
YoungAxelrodTheSniper
YoungAxelrodTheSniper Jul. 10 at 4:01 PM
$REGN puts
2 · Reply
Unicorn2020
Unicorn2020 Jul. 10 at 2:11 PM
$REGN The stock is breaking out, $600 is coming soon.
1 · Reply
BenTheDo
BenTheDo Jul. 10 at 2:08 PM
$REGN Anyone know what time the news is out today?
3 · Reply
trading__analysis
trading__analysis Jul. 10 at 2:52 AM
but TBH, I’m constantly in and out of things.. I wouldn’t hold all of these forever, but maybe a few to look at. $REGN as well, $ASAN but my entry is currently up 6.3% for ASAN
0 · Reply
EmbraceVolatility
EmbraceVolatility Jul. 9 at 6:58 PM
$REGN PDUFA tomorrow?
1 · Reply
bennfine
bennfine Jul. 9 at 3:34 PM
$REGN that was a weird morning. Up nice then down..ugh.
1 · Reply
gargoyl
gargoyl Jul. 9 at 3:00 PM
$BLRX longs who know where we have been see the future as bright here. The company foundation given Phil’s tireless pursuit of changing lives has not only strengthened the balance sheet but provides powerful catalyst 🐈‍⬛ for surprise growth not to mention PDAC advances in trials with esteemed partnerships and collaborations. The website is available for DD. The chart now has reached a perfect storm momentum on trend and pivots to warrant close attention to a breakout . $XBI $REGN Longest the 🦋
0 · Reply
Quantumup
Quantumup Jul. 9 at 2:21 PM
Jefferies⬇️ $VRNA to Hold/$107 from Buy/$140 and said "we see no FTC risks," after $MRK's acquisition bid for $VRNA. $TRVI $INSM $REGN - SNY AMGN GSK Jefferies said in its note: "Expected to close in Q4:25, Merck will acquire $VRNA for $107/sh (~23% premium) in return for Ohtuvayre, a novel PDE3/4 nebulizer for COPD. The implied ~$10B acquisition value suggests $3-3.5B+ in peak sales potential (based on a 3x multiple), which could be conservative as Ohtuvayre is in the midst of having the strongest COPD launch in history. We recently raised our peak sales by $1B to $4B based on our doctor survey. We see no FTC risks."
0 · Reply